Dear All, The G7 Health Ministers met 19-20 May 2022 in Berlin. As you might expect, their communique covered a range of topics but focused on four priority areas: (1) Overcoming COVID-19, (2) Future pandemic preparedness, (3) AMR, and (4) Health risks from climate change. You should review the entire communique; I will excerpt from
Notable reports: Incentives (WHO, AMR Hub); Strategy (BARDA); Capacity Building (UK Fleming Fund, US CDC)
Dear All, Four big reports have recently been released and are very much worth reviewing. First, the Global AMR R&D Hub and the WHO AMR Team have written a report entitled “Incentivising the development of new antibacterial treatments“. This report is a response to a 2021 request by the G7 Finance Ministers for a report on
Dear All, On the heels of yesterday’s (i) patient-focused meeting at the Capitol yesterday where 5 Members of Congress spoke in person (video, press release) in support of passage of the PASTEUR Act and (ii) strong shout-out to PASTEUR by Congressman Mike Doyle during the Energy and Commerce Committee markup session, CARB-X today announced commitments of
Dear All, Building on last year’s call from PFID to declare 18 May the annual “Squash Superbugs Day of Action,” we have a flurry of activity beginning tomorrow. See the list just below and participate as much as you can — the hashtag #SquashSuperbugs is highly recommended for your social media posts! In addition to just
Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures
Dear All: For your weekend reading list, I have some papers on the topic of (mostly pull) incentives for antibiotics. First, I previously wrote about the survey from TATFAR (Transatlantic Task Force on Antimicrobial Resistance) of 6 possible pull models (higher reimbursement, diagnostic confirmation, market entry rewards both fully and partially delinked, tradable exclusivity vouchers, and an options market).
UK Pull (Netflix) pilot: STEDI-based QALY value of new antibiotics implies societal value > 10m GBP/year!
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), We’ve written before about the UK’s “Netflix” pilot antibiotic Pull incentive in which England leads the way on showing how it plans to provide its fair share of a global antibacterial Pull incentive (for background on Pull incentives, see this superb 5-minute video explainer). In
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact
Dear All (and with thanks to ATMF’s Damiano de Felice for co-authoring this newsletter), Last week, the team at ATMF (Access to Medicine Foundation) released a 3rd update to the AMR Benchmark series that they started in 2018. For those not familiar with the ATMF, its independent analyses (all its funding is from governments or private
Dear All: Three recent papers bring together an instructive perspective on Pull incentives for the #FireExtinguishersOfMedicine. The first two papers survey the available tools and conclude that subscription models (e.g. “Netflix”) and transferable exclusivity vouchers (TEVs) are the key paths forward. The 3rd paper is new (and big) news: it shows that the existence of